Patents by Inventor William L. Mengeling
William L. Mengeling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8747859Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: February 20, 2009Date of Patent: June 10, 2014Assignees: The United States of America, as Represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Patent number: 8741309Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: July 24, 2006Date of Patent: June 3, 2014Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Patent number: 8491916Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: July 24, 2006Date of Patent: July 23, 2013Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Publication number: 20110104201Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: ApplicationFiled: February 20, 2009Publication date: May 5, 2011Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Patent number: 7081342Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: September 3, 2003Date of Patent: July 25, 2006Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
-
Publication number: 20040087002Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: ApplicationFiled: September 3, 2003Publication date: May 6, 2004Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
-
Patent number: 6660513Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.Type: GrantFiled: May 9, 2002Date of Patent: December 9, 2003Assignees: USDA, Boehringer Ingelheim Corp.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Patent number: 6641819Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: October 18, 2001Date of Patent: November 4, 2003Assignees: USDA, Boehringer Ingelheim Corp.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
-
Publication number: 20030119170Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: ApplicationFiled: October 18, 2001Publication date: June 26, 2003Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
-
Publication number: 20030072771Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.Type: ApplicationFiled: May 9, 2002Publication date: April 17, 2003Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Patent number: 6015663Abstract: A test based on restriction enzyme analysis identifies and differentiates strains of porcine reproductive and respiratory syndrome virus (PRRSV). Amplified cDNA from the ORF 5 region of the viral genome has been targeted for identification of unique restriction sites that allow for the differentiation of the vaccine strain from field strains, and for differentiation of field strains from each other through the use of selected restriction enzymes. This assay is useful for both clinical diagnosis of PRRSV field strains in vaccinated pigs as well as for epidemiological studies in the evaluation of the source and transmission of PRRS field viruses.Type: GrantFiled: March 1, 1996Date of Patent: January 18, 2000Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Ronald D. Wesley, Deborah F. Clouser, William L. Mengeling, Vladimir G. Andreyev, Ann C. Vorwald, Kelly M. Lager
-
Patent number: 5976537Abstract: Vaccines against porcine reproductive and respiratory syndrome (PRRS) have been produced by attenuation of wild type strains of the virus selected from the group of attenuated NADC-8, attenuated NADC-9 and attenuated NVSL-14. These vaccines are useful in monovalent, bivalent or polyvalent vaccines.Type: GrantFiled: July 2, 1996Date of Patent: November 2, 1999Assignee: The United States of America as represented by the Secretary of AgricultureInventors: William L. Mengeling, Kelly M. Lager, Ann C. Vorwald